Rosacea is a common inflammatory skin condition that affects more than 16 million people in the US.1

ROSACEA

Rosacea is a chronic condition characterized by facial redness, flushing, and visible blood vessels. Papulopustular rosacea can result in redness, swelling, and/or pus-filled bumps. There may be several factors that contribute to the cause of rosacea, including genetics, environmental factors, an overactive immune system, and Demodex mites.1-3

Front facing view of Rosacea
demodex mite

Demodex mites are highly prevalent in the skin of patients with rosacea and may contribute to the inflammatory response associated with the disease.3,4

side arrow shape
Photo of cheek showing Rosacea impact

Identifying the disease

Rosacea signs and symptoms often vary by individual and regularly fluctuate between periods of exacerbation, often referred to as a “flare up,” and remission.2,5 Common rosacea triggers include (but are not limited to)6,7:

  • Alcohol or spicy foods
  • Emotional stress or physical exertion, like exercise
  • Extreme temperatures
  • Certain medications, cosmetics, or skincare products

There are no preventative or curative therapies for rosacea.5 The mainstay of therapy for papulopustular rosacea includes topical and oral antimicrobials,7 but the condition can be challenging to treat.8

An investigational therapeutic is being studied for the treatment of papulopustular rosacea9

Learn about TP-04

References

1. Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018;7:F1000 Faculty Rev-1885.
2. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584-587. 3. Chang YS and Huang YC. Role of Demodex mite infestation in rosacea: A systemic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):441-447. 4. Forton FMN. The Pathogenic Role of Demodex Mites in Rosacea: A Potential Therapeutic Target Already in Erythematotelangiectatic Rosacea? Dermatol Ther (Heidelb). 2020;10(6):1229-1253. 5. Rainer B, Kang S, Chien AL. Rosacea: Epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2017;9(1):e1361574. 6. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327-341. 7. McGregor SP, Alinia H, Snyder A, Tuchayi SM, Fleischer A Jr, Feldman SR. A Review of the current modalities for the treatment of papulopustular rosacea. Dermatol Clin. 2018;36(2):135-150. 8. Zhang H, Tang K, Wang Y, Fang R, Sun Q. Rosacea treatment: review and update. Dermatol Ther (Heidelb). 2021;11(1):13-24. 9. Rosacea pipeline update: Tarsus starts phase 2A trial of TP-04 in PPR. Practical Dermatology. Published March 14, 2023. Accessed August 11, 2023. https://practicaldermatology.com/news/rosacea-pipeline-update-tarsus-starts-phase-2a-trial-of-tp-04-in-ppr

Contact Tarsus

Please reach out to us using the form below.

"*" indicates required fields

Opt-in
This field is for validation purposes and should be left unchanged.